InflaRx (IFRX) Competitors $2.04 0.00 (0.00%) (As of 10:15 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IFRX vs. ZVRA, TERN, RGNX, ESPR, ALMS, XERS, MGTX, YMAB, SIGA, and KRROShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Zevra Therapeutics (ZVRA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), Esperion Therapeutics (ESPR), Alumis (ALMS), Xeris Biopharma (XERS), MeiraGTx (MGTX), Y-mAbs Therapeutics (YMAB), SIGA Technologies (SIGA), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Zevra Therapeutics Terns Pharmaceuticals REGENXBIO Esperion Therapeutics Alumis Xeris Biopharma MeiraGTx Y-mAbs Therapeutics SIGA Technologies Korro Bio InflaRx (NASDAQ:IFRX) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking. Does the MarketBeat Community believe in IFRX or ZVRA? InflaRx received 208 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 64.58% of users gave InflaRx an outperform vote. CompanyUnderperformOutperformInflaRxOutperform Votes23764.58% Underperform Votes13035.42% Zevra TherapeuticsOutperform Votes29100.00% Underperform VotesNo Votes Which has better earnings & valuation, IFRX or ZVRA? Zevra Therapeutics has higher revenue and earnings than InflaRx. Zevra Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$70K1,715.93-$46.18M-$1.08-1.89Zevra Therapeutics$27.46M17.48-$46.05M-$1.97-4.56 Do analysts rate IFRX or ZVRA? InflaRx currently has a consensus target price of $8.00, suggesting a potential upside of 292.16%. Zevra Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 133.59%. Given InflaRx's higher possible upside, research analysts plainly believe InflaRx is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is IFRX or ZVRA more profitable? Zevra Therapeutics has a net margin of -342.63% compared to InflaRx's net margin of -33,362.70%. InflaRx's return on equity of -65.98% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InflaRx-33,362.70% -65.98% -56.86% Zevra Therapeutics -342.63%-159.54%-51.50% Does the media favor IFRX or ZVRA? In the previous week, Zevra Therapeutics had 23 more articles in the media than InflaRx. MarketBeat recorded 35 mentions for Zevra Therapeutics and 12 mentions for InflaRx. Zevra Therapeutics' average media sentiment score of 0.25 beat InflaRx's score of 0.14 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders & institutionals believe in IFRX or ZVRA? 42.4% of InflaRx shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, IFRX or ZVRA? InflaRx has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. SummaryZevra Therapeutics beats InflaRx on 11 of the 19 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.12M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-1.894.9789.5613.60Price / Sales1,715.93371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book1.6710.306.976.33Net Income-$46.18M$153.61M$119.04M$225.93M7 Day Performance0.49%-1.73%-1.78%-0.96%1 Month Performance33.33%-7.26%-3.59%1.06%1 Year Performance39.73%31.10%31.64%26.59% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx3.0863 of 5 stars$2.04flat$8.00+292.2%+34.2%$120.12M$70,000.00-1.8960Gap UpZVRAZevra Therapeutics3.4632 of 5 stars$8.99+0.2%$21.00+133.6%+100.2%$479.89M$27.46M-4.5565Analyst ForecastAnalyst RevisionTERNTerns Pharmaceuticals4.327 of 5 stars$5.56-0.7%$27.25+390.1%+49.3%$472.27M$1M0.0040RGNXREGENXBIO4.4239 of 5 stars$9.40-2.4%$35.27+275.2%-51.9%$465.68M$90.24M-1.91344Analyst ForecastAnalyst RevisionESPREsperion Therapeutics3.9536 of 5 stars$2.36-2.1%$8.17+246.0%+97.5%$465.01M$116.33M-3.77240Analyst ForecastALMSAlumisN/A$9.77+1.3%$26.83+174.7%N/A$461.34MN/A0.00N/AAnalyst RevisionXERSXeris Biopharma3.9457 of 5 stars$3.09+1.0%$4.87+57.5%+68.1%$460.66M$163.91M0.00290MGTXMeiraGTx4.3185 of 5 stars$5.83+0.2%$23.50+303.1%+2.8%$455.61M$14.02M0.00300Analyst ForecastYMABY-mAbs Therapeutics3.3273 of 5 stars$10.12-4.0%$21.38+111.2%+100.8%$453.28M$84.82M0.00150Analyst ForecastSIGASIGA Technologies0.9671 of 5 stars$6.33+1.3%N/A+20.9%$451.96M$139.92M5.2140Analyst RevisionKRROKorro Bio2.7373 of 5 stars$48.19+2.5%$142.17+195.0%+24.8%$451.54M$14.07M0.0070Analyst Revision Related Companies and Tools Related Companies Zevra Therapeutics Competitors Terns Pharmaceuticals Competitors REGENXBIO Competitors Esperion Therapeutics Competitors Alumis Competitors Xeris Biopharma Competitors MeiraGTx Competitors Y-mAbs Therapeutics Competitors SIGA Technologies Competitors Korro Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IFRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IFRX Stock Alerts